Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8375486 | 0.83 | MEN1 (0.47) | ESR2 | |
| SCHEMBL4365850 | 0.81 | ALDH1A1 (0.58) | ESRRAALDH1A1CYP2A6HSD17B10PGR | |
| SCHEMBL11029113 | 0.81 | ESRRA (0.43) | ESRRAALDH1A1CYP2A6IDO1HSD17B10 | |
| SCHEMBL8936775 | 0.81 | SLC6A2 (0.55) | ESRRAALDH1A1CYP2A6KDM4EHPGD | |
| SCHEMBL5032967 | 0.80 | CYP3A4 (0.44) | ESR1ESR2 | |
| Phenol SCHEMBL15641995 | 0.77 | KDM4E (0.50) | ESRRAALDH1A1HSD17B10PGRGAA | |
| SCHEMBL13871447 | 0.77 | CYP1A2 (0.46) | ESR1ALDH1A1HSD17B10MCL1ESR2 | |
| Ethane SCHEMBL10636467 | 0.76 | HTR1B (0.50) | ESRRAALDH1A1CYP2A6HSD17B10PGR | |
| SCHEMBL442767 | 0.76 | HTR1B (0.54) | ESRRAALDH1A1CYP2A6HSD17B10PGR | |
| SCHEMBL29577853 | 0.76 | HTR1B (0.54) | ESRRAALDH1A1CYP2A6HSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-0966436-B1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| EP-0966436-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998037061-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | ESRRA 3684/4885ESR1 4319/4885ALDH1A1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.